Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2A Single Dose, Open Label Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4

NCT04707573 is registered in ClinicalTrials.gov with Akebia Therapeutics as lead sponsor.

NCT NCT04707573
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04707573 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2A Single Dose, Open Label Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Subjects With Chronic Kidney Disease (CKD), Stages 3 and 4
Lead sponsor
Akebia Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
July 8, 2010
Completion date
September 24, 2010
Enrollment
22 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease